According to MacroGenics's latest financial reports the company's current earnings (TTM) are -$9.06 M. In 2022 the company made an earning of -$0.12 B an increase over its 2021 earnings that were of -$0.21 B.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$9.06 M | -92.44% |
2022 | -$0.12 B | -40.75% |
2021 | -$0.21 B | 55.79% |
2020 | -$0.13 B | -14.54% |
2019 | -$0.16 B | -11.46% |
2018 | -$0.18 B | 773.65% |
2017 | -$19.63 M | -66.47% |
2016 | -$58.53 M | 190.61% |
2015 | -$20.14 M | -47.43% |
2014 | -$38.32 M | 14585.78% |
2013 | -$0.27 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Pfizer PFE | $3.26 B | -36,167.56% | ๐บ๐ธ USA |
Eli Lilly LLY | $6.55 B | -72,462.55% | ๐บ๐ธ USA |
Amgen AMGN | $7.85 B | -86,818.92% | ๐บ๐ธ USA |
Gilead Sciences GILD | $6.85 B | -75,823.12% | ๐บ๐ธ USA |
Merck MRK | $3.03 B | -33,606.29% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | -$5.85 B | 64,439.63% | ๐บ๐ธ USA |
Xencor XNCR | -$0.13 B | 1,229.64% | ๐บ๐ธ USA |